VALNEVA SE (VLA.PA)

Company Profile

Valneva SE is a specialty vaccine company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 778 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Company Info

VALNEVA SE

6 rue Alain Bombard

Saint-Herblain PAYS DE LA LOIRE

P: 33228073710

Employees: 778

Website: https://valneva.com/